BR112015009070A2 - proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas - Google Patents
proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentasInfo
- Publication number
- BR112015009070A2 BR112015009070A2 BR112015009070A BR112015009070A BR112015009070A2 BR 112015009070 A2 BR112015009070 A2 BR 112015009070A2 BR 112015009070 A BR112015009070 A BR 112015009070A BR 112015009070 A BR112015009070 A BR 112015009070A BR 112015009070 A2 BR112015009070 A2 BR 112015009070A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- cocktail
- mycobacterium
- antigens
- virulent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201200652 | 2012-10-23 | ||
| DKPA201200654 | 2012-10-23 | ||
| DKPA201200653 | 2012-10-23 | ||
| DKPA201300477 | 2013-08-23 | ||
| PCT/DK2013/000070 WO2014063704A2 (en) | 2012-10-23 | 2013-10-18 | M. tuberculosis vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015009070A2 true BR112015009070A2 (pt) | 2017-07-04 |
Family
ID=49679267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015009070A BR112015009070A2 (pt) | 2012-10-23 | 2013-10-18 | proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9526773B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2912056B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6470179B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104736555B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015009070A2 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2015DN03962A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014063704A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201503467B (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3092000A1 (en) * | 2014-01-09 | 2016-11-16 | Transgene SA | Fusion of heterooligomeric mycobacterial antigens |
| WO2015161853A1 (en) * | 2014-04-24 | 2015-10-29 | Statens Serum Institut | New m.tuberculosis vaccines |
| WO2017055235A1 (en) * | 2015-09-30 | 2017-04-06 | Boehringer Ingelheim Vetmedica Gmbh | Improved modular antigen transportation molecules and uses therof in animals |
| CN105218681B (zh) * | 2015-10-21 | 2019-06-25 | 中山大学 | 一种用于诱导外周血单个核细胞产生结核特异性细胞因子的融合蛋白 |
| CN105218680B (zh) * | 2015-10-21 | 2019-06-25 | 中山大学 | 一种用于诱导外周血单个核细胞产生细胞因子的结核分支杆菌融合蛋白 |
| CN105567660B (zh) * | 2016-01-08 | 2018-11-20 | 中国人民解放军第四军医大学 | 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用 |
| EP3458088A2 (en) * | 2016-05-21 | 2019-03-27 | Infectious Disease Research Institute | Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections |
| AU2017280065B2 (en) | 2016-06-22 | 2021-07-01 | International Aids Vaccine Initiative, Inc. | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| EP3555630B1 (en) | 2016-12-14 | 2023-05-31 | Becton, Dickinson and Company | Methods and compositions for obtaining a tuberculosis assessment in a subject |
| CA3052084A1 (en) * | 2017-01-09 | 2018-07-12 | Biomunex Pharmaceuticals | A polypeptide linker for preparing multispecific antibodies |
| WO2019079155A1 (en) * | 2017-10-17 | 2019-04-25 | International Aids Vaccine Initiative, Inc. | CASSETTES OF ANTIGENS OF TUBERCULOSIS |
| WO2020249756A1 (en) | 2019-06-14 | 2020-12-17 | Statens Serum Institut | Fusion proteins for tuberculosis vaccines |
| US12599655B2 (en) | 2019-08-01 | 2026-04-14 | Trustees Of Tufts College | Neisseria gonorrhoeae vaccine compositions and methods of selecting antigens |
| CN110590958B (zh) * | 2019-09-11 | 2021-04-13 | 中国人民解放军总医院第八医学中心 | 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用 |
| CN116284283A (zh) * | 2021-12-13 | 2023-06-23 | 江苏瑞科生物技术股份有限公司 | 重组结核分枝杆菌抗原、其制备方法和应用 |
| CN118765203A (zh) | 2022-02-21 | 2024-10-11 | 史坦恩斯血清研究所 | 一种新型阳离子佐剂组合物 |
| CN115300618B (zh) * | 2022-05-11 | 2026-03-27 | 中国农业大学 | 基于牛β防御素5的结核疫苗及其在预防结核病中的应用 |
| CN115184603B (zh) * | 2022-06-30 | 2024-02-06 | 首都医科大学附属北京胸科医院 | EspC蛋白在制备结核分枝杆菌分离或富集产品中的应用 |
| KR20250087737A (ko) * | 2023-12-06 | 2025-06-17 | 주식회사 미코라파 | 결핵균에 대한 살균면역을 유도하는 융합단백질을 포함하는 결핵 백신 조성물 |
| CN118108815B (zh) * | 2024-04-23 | 2024-07-23 | 成都康华生物制品股份有限公司 | 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用 |
| US20250387462A1 (en) * | 2024-06-21 | 2025-12-25 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and vaccine for the prevention of tuberculosis or other mycobacterial infections |
| CN121591854A (zh) * | 2024-08-14 | 2026-03-03 | 首都医科大学附属北京胸科医院 | 一种结核病mRNA疫苗及其制备方法与应用 |
| CN121591853A (zh) * | 2024-08-14 | 2026-03-03 | 首都医科大学附属北京胸科医院 | 一种结核病mRNA疫苗及其制备方法与应用 |
| CN119823286B (zh) * | 2025-01-16 | 2026-02-06 | 中国动物卫生与流行病学中心 | 一种重组蛋白抗原及其在制备用于检测牛伽马干扰素试剂盒中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9909472A (pt) * | 1998-04-07 | 2001-09-11 | Corixa Corp | Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica |
| DE60236573D1 (de) * | 2002-04-05 | 2010-07-15 | Pasteur Institut | Identifizierung der Virulenz-assoziierten Regionen RD1 und RD5, die die Entwicklung von verbesserten Impfstoffen mit M. bovis BCG und M. microti ermöglicht |
| EP2421557B1 (en) * | 2009-04-24 | 2018-12-05 | Statens Serum Institut | A tuberculosis tb vaccine to prevent reactivation |
| US20130345079A1 (en) * | 2010-10-27 | 2013-12-26 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
-
2013
- 2013-10-18 EP EP13798236.9A patent/EP2912056B1/en active Active
- 2013-10-18 US US14/437,998 patent/US9526773B2/en not_active Expired - Fee Related
- 2013-10-18 IN IN3962DEN2015 patent/IN2015DN03962A/en unknown
- 2013-10-18 CN CN201380054841.4A patent/CN104736555B/zh not_active Expired - Fee Related
- 2013-10-18 BR BR112015009070A patent/BR112015009070A2/pt not_active IP Right Cessation
- 2013-10-18 JP JP2015537146A patent/JP6470179B2/ja not_active Expired - Fee Related
- 2013-10-18 WO PCT/DK2013/000070 patent/WO2014063704A2/en not_active Ceased
-
2015
- 2015-05-18 ZA ZA2015/03467A patent/ZA201503467B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2912056B1 (en) | 2020-02-12 |
| WO2014063704A3 (en) | 2014-06-19 |
| IN2015DN03962A (cg-RX-API-DMAC7.html) | 2015-10-02 |
| JP2015536309A (ja) | 2015-12-21 |
| WO2014063704A8 (en) | 2015-07-30 |
| ZA201503467B (en) | 2016-11-30 |
| CN104736555B (zh) | 2019-06-21 |
| JP6470179B2 (ja) | 2019-02-13 |
| US20150290311A1 (en) | 2015-10-15 |
| EP2912056A2 (en) | 2015-09-02 |
| CN104736555A (zh) | 2015-06-24 |
| US9526773B2 (en) | 2016-12-27 |
| WO2014063704A2 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016023778A2 (pt) | proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas | |
| IN2015DN03962A (cg-RX-API-DMAC7.html) | ||
| UA114502C2 (uk) | Вакцина mycoplasma hyopneumoniae | |
| WO2016176624A3 (en) | Porcine pestvirus, vaccines, and assays | |
| BR112016028816A2 (pt) | combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit. | |
| BR112014011229A2 (pt) | composições e métodos para o tratamento de citomegalovírus | |
| MY173004A (en) | Mycobacterial antigen vaccine | |
| BR112016022814A8 (pt) | composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico | |
| BR112016015422A2 (pt) | formulações de vacina de frasco único | |
| BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
| BR112021025172A2 (pt) | Proteínas de fusão para vacinas de tuberculose | |
| EA201790239A1 (ru) | Молекула-носитель для антигенов | |
| WO2006136162A3 (en) | Tuberculosis vaccines comprising antigens expressed during the latent infection phase | |
| MX2018013172A (es) | Metodos para el tratamiento de las enfermedades en las que es perjudicial la actividad de la il-13, a traves del uso de los anticuerpos anti-il-13. | |
| EA201892568A1 (ru) | Способы получения контрастных средств для ультразвукового исследования | |
| BRPI1006452A2 (pt) | vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo | |
| CO2018012506A2 (es) | Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre | |
| BR112013000345A2 (pt) | composições antigênicas para vírus sincicial respiratório e métodos | |
| BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
| MX380411B (es) | Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus. | |
| MX2016013277A (es) | Vacuna para estreptococo de grupo a. | |
| WO2015144732A3 (en) | Uses of parasite macrophage migration inhibitory factors | |
| BR112014020025A8 (pt) | Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
| MX388527B (es) | Composiciones adyuvantes y metodos relacionados. | |
| AR093530A1 (es) | Adyuvante de vacunacion, preparacion, y vacunas que lo contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |